Cellectis (CLLS) Other financing activities (2020 - 2023)
Cellectis (CLLS) posted quarterly Other financing activities of $1.3 million for Q2 2023, up 417.16% year-over-year from $246536.8 in Q2 2022, and up 151.98% quarter-over-quarter from $506000.0 in Q1 2023.
Analysis
Cellectis (CLLS) Other financing activities (2020 - 2023) Analysis & Trends
Cellectis' Other financing activities history runs 4 years deep, the most recent figure standing at $1.3 million for Q2 2023.
- In Q2 2023, Other financing activities rose 417.16% year-over-year to $1.3 million; the TTM figure through Sep 2023 stood at $478000.0 (down 94.58% YoY), while the FY2015 annual figure was $349.1 million, up 133.73% from the prior year.
- Other financing activities for Q2 2023 stood at $1.3 million, up from $506000.0 in the prior quarter.
- The five-year high for Other financing activities was $11.8 million in Q1 2021, with the low at -$1.3 million in Q3 2022.
- The 4-year median for Other financing activities is $269000.0 (2020), against an average of $2.8 million.
- The sharpest annual moves came in 2022 and 2023: Other financing activities tumbled 1397.7% in 2022, then jumped 417.16% in 2023.
- Cellectis' Other financing activities stood at $32000.0 in 2020, then slumped by 371.88% to -$87000.0 in 2021, then sank by 1397.7% to -$1.3 million in 2022, then jumped by 197.85% to $1.3 million in 2023.
- Business Quant data shows CLLS's Other financing activities at $1.3 million in Q2 2023, $506000.0 in Q1 2023, and -$1.3 million in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 506,000.00 |
| Dec 31, 2022 | -254,000.00 |
| Sep 30, 2022 | -1.30 Mn |
| Jun 30, 2022 | -402,000.00 |
| Mar 31, 2022 | 10.61 Mn |
| Dec 31, 2021 | -130,000.00 |
| Sep 30, 2021 | -87,000.00 |
| Mar 31, 2021 | 11.82 Mn |
| Dec 31, 2020 | 133,000.00 |
| Sep 30, 2020 | 32,000.00 |